Data Insights

Dexmedetomidine by BioXcel Therapeutics for Alcohol Dependence: Likelihood of Approval

Dexmedetomidine is under clinical development by BioXcel Therapeutics and currently in Phase I for Alcohol Dependence. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine in Alcohol Dependence

Data Insights

Dexmedetomidine by BioXcel Therapeutics for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Dexmedetomidine is under clinical development by BioXcel Therapeutics and currently in Phase I for Post-Traumatic Stress Disorder (PTSD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine in Post-Traumatic Stress Disorder (PTSD)

Data Insights

Dexmedetomidine by BioXcel Therapeutics for Alzheimer's Disease: Likelihood of Approval

Dexmedetomidine is under clinical development by BioXcel Therapeutics and currently in Phase III for Alzheimer's Disease. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine in Alzheimer's Disease

Data Insights

Dexmedetomidine by BioXcel Therapeutics for Bipolar Disorder (Manic Depression): Likelihood of Approval

Dexmedetomidine is under clinical development by BioXcel Therapeutics and currently in Phase I for Bipolar Disorder (Manic Depression). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine in Bipolar Disorder (Manic Depression)

Data Insights

Talabostat by BioXcel Therapeutics for Solid Tumor: Likelihood of Approval

Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Talabostat in Solid Tumor

Data Insights

Talabostat by BioXcel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Talabostat in Pancreatic Ductal Adenocarcinoma

Data Insights

Talabostat by BioXcel Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talabostat in Relapsed Acute Myeloid Leukemia

Data Insights

Talabostat by BioXcel Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talabostat in Refractory Acute Myeloid Leukemia

Data Insights

Talabostat by BioXcel Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Talabostat in Myelodysplastic Syndrome